DCTHDelcath Systems Inc.Signing up patients
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
Refractory Metastatic Colorectal Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 90 (planned)
- Started
- Aug 5, 2025
- Main results expected
- Dec 2026
- Fully finished
- Oct 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
hPFS
Measured over: time from randomization to the first occurrence of hepatic disease progression, assessed over 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06607458 · record last updated 2026-10-20 · checked 2026-11-09 15:47 UTC